NICE has 'done all we can' to ne­go­ti­ate for En­her­tu cov­er­age, reaf­firms de­ci­sion not to rec­om­mend

The UK’s drug pric­ing body has af­firmed its ear­li­er de­ci­sion not to rec­om­mend cov­er­age of As­traZeneca and Dai­ichi Sankyo’s breast can­cer treat­ment En­her­tu.

“As we …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER